Oncotarget

Research Papers:

Overexpression of mutant Ptch in rhabdomyosarcomas is associated with promoter hypomethylation and increased Gli1 and H3K4me3 occupancy

Frauke Nitzki _, Ezequiel J. Tolosa, Nicole Cuvelier, Anke Frommhold, Gabriela Salinas-Riester, Steven A. Johnsen, Martin E. Fernandez-Zapico and Heidi Hahn

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:9113-9124. https://doi.org/10.18632/oncotarget.3272

Metrics: PDF 791 views  |   HTML 1282 views  |   ?  


Abstract

Frauke Nitzki1, Ezequiel J. Tolosa2, Nicole Cuvelier1, Anke Frommhold1, Gabriela Salinas-Riester3, Steven A. Johnsen4, Martin E. Fernandez-Zapico2, Heidi Hahn1

1Department of Human Genetics, University Medical Center, Göttingen, Germany

2Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, MN, USA

3Microarray and Deep-Sequencing Core Facility, University Medical Center, Göttingen, Germany

4Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany

Correspondence to:

Frauke Nitzki, e-mail: fnitzki@gwdg.de

Keywords: RMS, Ptch, Gli1, DNA hypomethylation, H3K4me3

Received: February 27, 2014     Accepted: February 05, 2015     Published: March 14, 2015

ABSTRACT

Mice with heterozygous loss of the tumor suppressor Patched1 (Ptch) develop rhabdomyosarcoma (RMS)-like tumors. However, Ptch transcripts are consistently overexpressed in these tumors. We have recently shown that the upregulated transcripts are derived from the mutated Ptch allele thus leading to the hypothesis that the wild-type allele is repressed during RMS development. Here we describe epigenetic changes taking place at the Ptch locus during RMS development. We showed a lower degree of DNA-methylation in methylation-sensitive CpG regions of the Ptch promoter in RMS compared to normal muscle from heterozygous Ptch animals. In agreement with these results, treatment of heterozygous Ptch mice with the DNA demethylating agent 5-aza-2-deoxycytidine (5-aza-dC) between embryonic days E9.5–E11.5 significantly accelerated RMS formation. Since Ptch promoter methylation occurs after/around E13.5, the window for RMS initiation during embryogenesis, these results provide additional evidence that Ptch promoter hypomethylation may contribute to RMS formation. We have also demonstrated increased trimethylation of histone H3 lysine 4 (H3K4me3) and preferential binding of Gli1, a known Ptch activator, to the mutant locus in RMS. Together, these findings support an alternative model for RMS formation in heterozygous Ptch mice including loss of methylation and concomitant occupancy by activating histone marks of mutant Ptch.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3272